Business Description
Hansoh Pharmaceutical Group Co Ltd
ISIN : KYG549581067
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.78 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 1.03 | |||||
Interest Coverage | 42.58 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.12 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.6 | |||||
3-Year EBITDA Growth Rate | 4.3 | |||||
3-Year EPS without NRI Growth Rate | 2 | |||||
3-Year FCF Growth Rate | 37.6 | |||||
3-Year Book Growth Rate | 10 | |||||
Future 3-5Y EPS without NRI Growth Rate | 12.13 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 99.95 | |||||
9-Day RSI | 98.12 | |||||
14-Day RSI | 92.34 | |||||
6-1 Month Momentum % | 2.73 | |||||
12-1 Month Momentum % | 2.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.21 | |||||
Quick Ratio | 4.12 | |||||
Cash Ratio | 3.62 | |||||
Days Inventory | 192.79 | |||||
Days Sales Outstanding | 121.94 | |||||
Days Payable | 81.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.82 | |||||
Dividend Payout Ratio | 0.22 | |||||
Forward Dividend Yield % | 1.45 | |||||
5-Year Yield-on-Cost % | 0.82 | |||||
Shareholder Yield % | 0.77 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.8 | |||||
Operating Margin % | 28.1 | |||||
Net Margin % | 32.44 | |||||
FCF Margin % | 27.26 | |||||
ROE % | 13.45 | |||||
ROA % | 10.28 | |||||
ROIC % | 26.74 | |||||
ROC (Joel Greenblatt) % | 81.51 | |||||
ROCE % | 14.62 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 32.06 | |||||
PE Ratio without NRI | 33.35 | |||||
Price-to-Owner-Earnings | 29.32 | |||||
PEG Ratio | 5.13 | |||||
PS Ratio | 9.95 | |||||
PB Ratio | 3.83 | |||||
Price-to-Tangible-Book | 3.84 | |||||
Price-to-Free-Cash-Flow | 36.63 | |||||
Price-to-Operating-Cash-Flow | 32.28 | |||||
EV-to-EBIT | 20.42 | |||||
EV-to-EBITDA | 18.64 | |||||
EV-to-Revenue | 7.75 | |||||
EV-to-FCF | 28.42 | |||||
Price-to-Projected-FCF | 2.29 | |||||
Price-to-Peter-Lynch-Fair-Value | 5.08 | |||||
Price-to-Graham-Number | 2.38 | |||||
Price-to-Net-Current-Asset-Value | 4.59 | |||||
Price-to-Net-Cash | 5.7 | |||||
Earnings Yield (Greenblatt) % | 4.9 | |||||
FCF Yield % | 2.78 | |||||
Forward Rate of Return (Yacktman) % | 8.77 |